DK0971878T3 - Aminforbindelser, fremstillingen og anvendelsen deraf som inhibitorer af amyloid-beta-produktion - Google Patents

Aminforbindelser, fremstillingen og anvendelsen deraf som inhibitorer af amyloid-beta-produktion

Info

Publication number
DK0971878T3
DK0971878T3 DK98905656T DK98905656T DK0971878T3 DK 0971878 T3 DK0971878 T3 DK 0971878T3 DK 98905656 T DK98905656 T DK 98905656T DK 98905656 T DK98905656 T DK 98905656T DK 0971878 T3 DK0971878 T3 DK 0971878T3
Authority
DK
Denmark
Prior art keywords
sup
sub
substituted
ring
inhibitors
Prior art date
Application number
DK98905656T
Other languages
English (en)
Inventor
Kaneyoshi Kato
Jun Terauchi
Mitsuru Kakihana
Hiroaki Fukumoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK0971878T3 publication Critical patent/DK0971878T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK98905656T 1997-02-27 1998-02-26 Aminforbindelser, fremstillingen og anvendelsen deraf som inhibitorer af amyloid-beta-produktion DK0971878T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP4394097 1997-02-27
JP19349797 1997-07-18
PCT/JP1998/000780 WO1998038156A1 (en) 1997-02-27 1998-02-26 Amine compounds, their production and use as amyloid-beta production inhibitors

Publications (1)

Publication Number Publication Date
DK0971878T3 true DK0971878T3 (da) 2008-06-30

Family

ID=26383777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98905656T DK0971878T3 (da) 1997-02-27 1998-02-26 Aminforbindelser, fremstillingen og anvendelsen deraf som inhibitorer af amyloid-beta-produktion

Country Status (11)

Country Link
US (3) US6310107B1 (da)
EP (1) EP0971878B1 (da)
AT (1) ATE390404T1 (da)
AU (1) AU6116698A (da)
CA (1) CA2276278C (da)
DE (1) DE69839305T2 (da)
DK (1) DK0971878T3 (da)
ES (1) ES2300119T3 (da)
HU (1) HU225960B1 (da)
PT (1) PT971878E (da)
WO (1) WO1998038156A1 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300119T3 (es) * 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide.
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JP2003528076A (ja) 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
US6784314B2 (en) * 2000-04-03 2004-08-31 Takeda Chemical Industries, Ltd. Process for producing amine derivatives
AU2001246844A1 (en) * 2000-04-07 2001-10-23 Takeda Chemical Industries Ltd. Soluble beta amyloid precursor protein secretion promoters
ATE479429T1 (de) * 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
WO2001087293A1 (fr) * 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Inhibiteurs de la ?-secretase
AU1074702A (en) 2000-11-02 2002-05-15 Merck Sharp & Dohme Sulfamides as gamma-secretase inhibitors
CA2428817C (en) * 2000-11-17 2010-06-01 Takeda Chemical Industries, Ltd. Copolyvidone-containing preparation
EP1382598A4 (en) * 2001-04-26 2005-03-23 Takeda Pharmaceutical NEW HETEROCYCLIC DERIVATIVES
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1459764A4 (en) * 2001-12-26 2006-08-16 Takeda Pharmaceutical REMEDIES AGAINST LIGHT COGNITIVE DISORDERS
CN100562516C (zh) 2001-12-27 2009-11-25 第一制药株式会社 β-淀粉样蛋白产生和分泌的抑制剂
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003229932B2 (en) 2002-05-01 2008-12-11 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
GB0225475D0 (en) * 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US7094790B2 (en) 2003-05-07 2006-08-22 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
ES2315663T3 (es) * 2003-06-24 2009-04-01 Pfizer Products Incorporated Procedimiento para la preparacion de derivados de 1-((benzoimidazol-1-il)quinolin-8-il)piperidin-4-ilamina.
PL379466A1 (pl) 2003-06-30 2006-09-18 Daiichi Sankyo Company , Limited Heterocykliczne pochodne metylosulfonu
CN1874991A (zh) 2003-08-29 2006-12-06 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
KR20110140139A (ko) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
CA2539042A1 (en) 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
EP1667958A2 (en) 2003-10-01 2006-06-14 The Procter & Gamble Company Melanin concentrating hormone antagonists
US20060247239A1 (en) * 2003-10-01 2006-11-02 Hu Xiufeng E Melanin concentrating hormone antagonists
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
ATE458727T1 (de) * 2004-05-05 2010-03-15 Hoffmann La Roche Zur modulation des 5-ht6-rezeptors, des 5-ht2a- rezeptors oder beider rezeptoren geeignete arylsulfonylbenzodioxane
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
WO2006001463A1 (ja) * 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
JP4318087B2 (ja) 2004-12-13 2009-08-19 小野薬品工業株式会社 アミノカルボン酸誘導体およびその医薬用途
DK1828177T3 (da) 2004-12-17 2008-11-17 Lilly Co Eli Hidtil ukendte MCH-receptorantagonister
WO2006066746A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-ht receptor ligands
PT1831159E (pt) * 2004-12-21 2010-03-03 Hoffmann La Roche Derivados de tetralina e de indano e as suas utilizações
AU2005318516B2 (en) 2004-12-21 2011-02-17 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of CNS disorders
ES2314749T3 (es) 2004-12-21 2009-03-16 F. Hoffmann-La Roche Ag Derivados de tetralina y de indano y usos de los mismos como antagonistas de 5-ht.
ES2332526T3 (es) * 2004-12-21 2010-02-08 F. Hoffmann-La Roche Ag Derivados de tetralina e indano y usos de los mismos.
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
TW200716583A (en) * 2005-04-22 2007-05-01 Wyeth Corp Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
WO2007051735A1 (en) * 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
CA2654822A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
CN101472884A (zh) * 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
JP2009541248A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホンアミジルテトラリン誘導体及びそれらの使用
WO2008124614A1 (en) 2007-04-06 2008-10-16 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CL2008000985A1 (es) 2007-04-06 2008-10-10 Neurocrine Biosciences Inc Compuesto derivado de heterociclos de nitrogeno, agonistas del receptor gnrh; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar una afeccion relacionada con las hormonas sexuales, endometriosis, dismenorrea, enfermedad de ov
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
US20100113472A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
PL2354134T3 (pl) 2008-12-05 2016-07-29 Astellas Pharma Inc Pochodne 2h-chromenowe jako stymulatory receptora 1-fosforanu sfingozyny
KR101095026B1 (ko) * 2009-01-23 2011-12-20 한국과학기술연구원 비스(스티릴)피리미딘 및 비스(스티릴)벤젠 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
CN105792832B (zh) 2013-10-04 2021-03-23 诺华股份有限公司 用于治疗乙肝病毒的有机化合物
EP3052464B1 (en) * 2013-10-04 2020-04-15 Novartis AG 3'end caps for rna-interferring agents for use in rna interference
EP2903204A1 (en) * 2014-02-03 2015-08-05 Tata Consultancy Services Limited A computer implemented system and method for lightweight authentication on datagram transport for internet of things
US11505528B2 (en) 2017-08-04 2022-11-22 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3630903A1 (de) 1986-09-11 1988-03-24 Thomae Gmbh Dr K Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
DE3807813A1 (de) 1988-03-10 1989-09-21 Thomae Gmbh Dr K Neue benzocycloheptenderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69211133T2 (de) 1991-03-01 1996-10-31 Zeria Pharmaceutical Co., Ltd., Tokio/Tokyo Indan-derivate als thromboxan-antagonisten
US5756496A (en) 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
ES2098186B1 (es) 1995-02-09 1998-02-01 Consejo Superior Investigacion Composiciones farmaceuticas a base de aminometilindoles para su aplicacion terapeutica como neuroprotectores en las enfermedades de parkinson y alzheimer.
AU3880097A (en) 1996-08-14 1998-03-06 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
US6048877A (en) * 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents
ES2300119T3 (es) * 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide.
TW450954B (en) * 1998-05-14 2001-08-21 Pharmacia & Amp Upjohn Company Phenylsulfonamide-phenylethylamines useful as dopamine receptors

Also Published As

Publication number Publication date
WO1998038156A1 (en) 1998-09-03
ES2300119T3 (es) 2008-06-01
US6613805B2 (en) 2003-09-02
DE69839305D1 (de) 2008-05-08
US20020032189A1 (en) 2002-03-14
PT971878E (pt) 2008-07-08
CA2276278A1 (en) 1998-09-03
US6310107B1 (en) 2001-10-30
EP0971878B1 (en) 2008-03-26
DE69839305T2 (de) 2009-04-09
EP0971878A1 (en) 2000-01-19
ATE390404T1 (de) 2008-04-15
AU6116698A (en) 1998-09-18
US7256204B2 (en) 2007-08-14
HUP0002476A3 (en) 2001-09-28
CA2276278C (en) 2009-04-07
US20040077867A1 (en) 2004-04-22
HU225960B1 (en) 2008-01-28
HUP0002476A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
DK0971878T3 (da) Aminforbindelser, fremstillingen og anvendelsen deraf som inhibitorer af amyloid-beta-produktion
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
NO20013254D0 (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
PE69299A1 (es) Compuestos calciliticos
ES2031595T3 (es) Dihidropiridinas.
DK0583485T3 (da) Ethanolaminderivater med sympathomimetiske og anti-pollakisuria-virkninger
PT98362A (pt) Processo para a preparacao de derivados de tioalquiltio-cefalosporina e de composicoes farmaceuticas que os contem
DE68926981D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung
EA200100090A3 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EP0351385A3 (en) New amidino and guanidino derivatives
HUP0203855A2 (hu) Szubsztituált piperazinszármazékok mint MTP inhibitorok, ezeket tartalmazó gyógyszerkészítmények és eljárás az előállításaikra
DK0813411T3 (da) Anvendelse af vincopetinderivater til hæmning af dannelse eller afsondring af amyloid -protein
DK0541263T3 (da) 5-Piperazinylalkyl-1,5-benzothiazepinoner, der er nyttige som calciumantagonister
RU95110868A (ru) Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
ES2010225A6 (es) Procedimiento de preparacion de nuevos derivados de piperazina diona-2,6.
SE9302437L (sv) N-Derivat av (fenyletyl-beta-ol)amin, ett förfarande för deras framställning och läkemedelskompositioner som innehåller desamma
BR0201312A (pt) Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos
TH2178EX (th) อนุพันธ์ของกรด w-อะมิโน การเตรียมและการใช้สารเหล่านี้ และสารผสมที่มีอนุพันธ์เหล่านี้
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.
TH32102A (th) สารประกอบแนพธิล สารอินเทอมิเดียท สารผสม และวิธีใช้
JPS56115768A (en) Serine derivative and its preparation